	US 12,478,646 B2
	Umbilical cord-derived adherent stem cells, preparation method therefor, and use thereof
Jeong Min Shin, Seongnam-si (KR); Ji Min Yu, Seongnam-si (KR); Jihye Kim, Suwon-si (KR); Ahreum Kang, Seongnam-si (KR); and Hye Sun Kim, Seongnam-si (KR)
Assigned to CHA BIOTECH CO., LTD., Seoul (KR)
Filed by CHA BIOTECH CO., LTD., Seoul (KR)
Filed on May 16, 2023, as Appl. No. 18/318,668.
Application 18/318,668 is a continuation of application No. 15/752,057, granted, now 11,690,877, previously published as PCT/KR2016/008887, filed on Aug. 12, 2016.
Claims priority of application No. 10-2015-0113858 (KR), filed on Aug. 12, 2015; and application No. 10-2016-0102721 (KR), filed on Aug. 12, 2016.
Prior Publication US 2023/0302059 A1, Sep. 28, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/50 (2015.01); A61K 35/51 (2015.01); A61P 9/00 (2006.01); A61P 25/00 (2006.01); A61P 37/00 (2006.01); C12N 5/0775 (2010.01); C12N 5/0789 (2010.01)

CPC A61K 35/50 (2013.01) [A61K 35/51 (2013.01); A61P 9/00 (2018.01); A61P 25/00 (2018.01); A61P 37/00 (2018.01); C12N 5/0665 (2013.01); C12N 5/0647 (2013.01); C12Y 304/24003 (2013.01)]

10 Claims

1. A composition comprising enhanced adherent stem cells that are isolated from a single source and cultured under a hypoxia condition and a pharmaceutically acceptable carrier, wherein the single source is a mammalian umbilical cord, and wherein the enhanced adherent stem cells have the following characteristics (a) to (d):

(a) maintaining the morphology of adherent fibroblasts during subculture;

(b) having ability to differentiate into adipocytes, osteocytes, and chondrocytes;

(c) having one or more surface antigen characteristics selected from the group consisting of CD200+, Tra1-60−, CD3−, CD1a−, CD11c−, CD16−, CD86a−, CD8a−, CD40−, CD141+, CD61+, CD87+, and MIC A/B−; and

(d) not expressing Oct4 and Nanog.